RYTARY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RYTARY (RYTARY).
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain, thereby increasing dopamine levels in the substantia nigra and striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, reducing peripheral side effects and increasing levodopa availability to the brain.
| Metabolism | Levodopa is extensively metabolized by aromatic L-amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) in the periphery and brain. Carbidopa inhibits peripheral AAAD. Major metabolic pathways include decarboxylation and O-methylation. |
| Excretion | Renal (approximately 80% as metabolites, including 3-O-methyldopa and other conjugates; <1% unchanged); biliary/fecal (approximately 10-15%) |
| Half-life | Carbidopa: 2-3 hours; Levodopa: 1-2 hours (immediate-release component), levodopa elimination half-life extended to approximately 5-6 hours for the extended-release component; clinical context: allows once-daily dosing despite short half-life of IR component due to ER formulation |
| Protein binding | Levodopa: approximately 10-30% (albumin); Carbidopa: approximately 36% (albumin) |
| Volume of Distribution | Levodopa: 0.66-1.4 L/kg (carbidopa: not well-characterized); Vd indicates extensive tissue distribution, particularly to muscle and brain |
| Bioavailability | Levodopa: Approximately 70-80% (from immediate-release component with carbidopa); overall absorption from RYTARY's extended-release formulation is about 80% relative to the same total dose of immediate-release carbidopa/levodopa |
| Onset of Action | Oral: Initial effect may be seen within 30 minutes to 2 hours for immediate-release component; peak plasma concentrations for total levodopa occur at approximately 3-5 hours for the extended-release component |
| Duration of Action | Oral: Approximately 24 hours with once-daily dosing due to extended-release formulation; clinical note: some patients may experience wearing-off requiring dose adjustments or additional IR therapy |
| Molecular Weight | 296.15 |
Initial: 23.75 mg/95 mg orally three times daily for 3 days, then increase to 36.25 mg/145 mg three times daily. Titrate based on response and tolerability. Maximum dose: 97.5 mg/390 mg three times daily.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No dose adjustment for mild to moderate renal impairment. Severe renal impairment (eGFR <30 mL/min/1.73 m²): not recommended due to potential accumulation of carbidopa and levodopa. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: use with caution, consider reducing dose by 50%. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients (age <18 years). |
| Geriatric use | Initiate at low end of dosing range; monitor for hallucinations, dizziness, and hypotension. Dose titration should be gradual due to increased sensitivity to levodopa and risk of adverse effects. |
| 1st trimester | Limited data; carbidopa-levodopa has been associated with increased risk of congenital malformations in animal studies. Use only if potential benefit justifies risk. |
| 2nd trimester | No well-controlled human studies; may be used if clearly needed. Monitor for maternal and fetal effects. |
| 3rd trimester | May cause uterine contractions and fetal distress. Avoid near term; consider risks of maternal hypotension and fetal hypoxia. |
Clinical note
Comprehensive clinical and safety monograph for RYTARY (RYTARY).
| Placental transfer | Levodopa crosses the placenta; carbidopa crosses to a lesser extent. Both have been detected in fetal tissues in animal studies. |
| Breastfeeding | Levodopa is excreted into breast milk in low concentrations. Carbidopa may reduce milk production. Monitor infant for potential adverse effects such as drowsiness or hypotonia. Caution is advised, especially in preterm or ill infants. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to carbidopa or levodopaConcurrent use with nonselective MAO inhibitorsNarrow-angle glaucomaSuspicious undiagnosed skin lesions or history of melanoma
| Precautions | May cause or exacerbate dyskinesias, May cause orthostatic hypotension, Risk of falls, May cause hallucinations and psychotic-like behavior, May cause impulse control disorders, May cause malignant melanoma (regular skin monitoring recommended), Dopamine dysregulation syndrome, May cause sleep attacks/sudden onset of sleep, May cause excessive daytime sleepiness, May cause hyperpyrexia and confusion if abruptly discontinued (neuroleptic malignant syndrome-like symptoms) |
| Food/Dietary | High-protein foods (e.g., meat, poultry, fish, dairy, nuts) can compete with levodopa for absorption across the gut and blood-brain barrier, potentially reducing efficacy. Avoid consuming high-protein meals within 1 hour before or after taking RYTARY. Consistency regarding food intake is recommended to minimize pharmacokinetic variability. Iron supplements or iron-containing multivitamins may decrease levodopa absorption; take at least 2 hours apart. |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited human data; animal studies show fetal developmental toxicity including malformations. Second/third trimester: Risk of adverse maternal effects (e.g., dyskinesias) and potential fetal effects due to levodopa crossing placenta. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal motor function, blood pressure, and signs of dyskinesias. Assess fetal growth and development via ultrasound. Consider fetal echocardiography for potential cardiac effects. Monitor for neonatal withdrawal syndrome (hypotonia, irritability) postpartum. |
| Fertility Effects | No direct evidence of impaired fertility in humans. Animal studies show altered reproductive parameters at high doses. In patients with Parkinson's, improved motor function may indirectly enhance fertility. Levodopa may increase prolactin, potentially affecting menstrual cycle. |
| Clinical Pearls | RYTARY (carbidopa/levodopa extended-release capsules) should be taken consistently with or without food to minimize bioavailability fluctuations. Capsules can be opened and sprinkled on soft food (e.g., applesauce) for patients with swallowing difficulties, but the entire contents must be consumed immediately. Avoid high-protein meals as they can reduce levodopa absorption. Dose adjustments may be needed when switching from immediate-release carbidopa/levodopa; monitor for dyskinesias and 'on-off' phenomena. RYTARY has a delayed onset of 1-2 hours, so it is not suitable for rapid symptom relief. Concomitant use with non-selective MAOIs is contraindicated due to hypertensive crisis risk. Pre-existing psychiatric conditions may worsen. |
| Patient Advice | Take RYTARY exactly as prescribed; do not crush or chew the capsules. · If you have difficulty swallowing, open the capsule and sprinkle the beads onto a spoonful of applesauce or pudding; swallow immediately without chewing. · Take doses at the same times each day, with or without food, but be consistent about your choice. · Avoid high-protein meals (e.g., meat, fish, dairy) close to taking this medication, as they may reduce its effectiveness. · Do not stop taking RYTARY suddenly without consulting your doctor, as this may cause a serious withdrawal syndrome (neuroleptic malignant syndrome). · You may experience dizziness, orthostatic hypotension, or nausea; rise slowly from sitting or lying positions and avoid hazardous activities until you know how the drug affects you. · Report any new or worsening involuntary movements (dyskinesias), mood changes, or hallucinations to your healthcare provider. · This medication may cause a reddish-brown discoloration of urine, sweat, or saliva; this is harmless. · Keep a diary of your 'on-off' times and motor responses to help your doctor adjust your dose. |